Th e list wa s s e l e c t e d b y t h e Gl o b a l FOF Ass o c i a ti o n t h r o u g h r e c omme n d a ti o n , e v a l u a ti o n a n d s c o ri n g b y i n v e stme n t a ss o c i a ti o n s i n Eu r o p e , Ame ri c a , t h e Mi d d l e Ea st a n d o t h e r r e g i o n s. Th e awa r d s i n c l u d e : 当前，全球私募股权投资行业已进入到发展的新周期，市场体系越发完善、主体更为多元、机 制更加健全。 Cu rr e n tl y, t h e g l o b a l p ri v a t e e q u it y i n v e stme n t i n d u str y h a s e n t e r e d a n ew e r a , wit h t h e ma r k e t b e c ...

Core Viewpoint - Sichuan Shuangma is focusing on developing its biopharmaceutical research and production business while maintaining its existing building materials manufacturing operations [1] Group 1: Company Operations - Sichuan Shuangma is engaged in industrial investment and management as well as private equity fund management [1] - The company is managing and participating in investments in multiple private equity funds across various sectors including smart manufacturing, semiconductors, new energy, new consumption, health care, and biotechnology [1] Group 2: Investment Philosophy - The company adheres to the philosophy of promoting industry through capital, supporting the development of the real economy [1]

以下文章来源于并购最前线 ，作者周佳丽 并购最前线 . 投资界（PEdaily.cn）旗下，专注并购动态 罕见Buyout案例。 作者/周佳丽 报道/投资界-并购最前线 又见KKR。 投 资 界 获 悉 ， KKR 宣 布 通 过 旗 下 美 元 基 金 及 人 民 币 基 金 ， 投 了 一 家 总 部 位 于 中 国 的 蘑 菇培养和真菌生物技术公司——施尔丰S y l v a n，并将继续作为其控股股东。 同 年 ， 江 苏 裕 灌 全 资 收 购 了 美 国 施 尔 丰 。 成 立 于 1 9 3 2 年 ， 施 尔 丰 是 一 家 蘑 菇 菌 种 和 真 菌生物技术企业，1 9 9 2年开始进入中国市场，后来在2 0 1 8年正式落户中国，改变了国 内 食 用 菌 行 业 依 赖 进 口 菌 种 的 现 状 。 2 0 1 9 年 初 ， 施 尔 丰 国 际 生 物 科 技 有 限 公 司 在 江 苏 淮安市注册成立，法定代表人为齐延全。 时至如今，施尔丰在全球运营着多个生产基地，为6 5个国家的客户提供服务，是世界上 最大的蘑菇菌种生产和分销商。 正 如 施 尔 丰 首 席 执 行 官 齐 延 全 ...

Group 1 - Nanchong Advanced Manufacturing Development Private Investment Fund Partnership has been established with a total investment of 3 billion yuan [1] - The fund's business scope includes private equity investment, investment management, and asset management activities [1] - The fund is co-funded by Nanchong Industrial Development Group Co., Ltd. and others [1] Group 2 - The fund is registered as a limited partnership and is located in Nanchong City, Sichuan Province [2] - The fund's operational period is from January 20, 2026, to January 20, 2041 [2] - Nanchong Industrial Development Group Co., Ltd. holds a 99.90% stake in the fund, contributing 2.997 billion yuan [2]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、合作投资基本概述情况 江苏立霸实业股份有限公司（以下简称"公司"）于 2026 年 1 月 14 日召开第十届董事会第十八次会议， 审议并通过了《关于公司参与出资设立投资基金暨关联交易的议案》，关联董事回避表决，同意公司本 次参与出资设立投资基金暨关联交易事项。公司与上海君泺企业管理合伙企业（有限合伙）和公司关联 方卢凤仙女士（本公司控股股东、实际控制人、董事长兼总经理）及其他 2 位有限合伙人共同签署了 《扬州君江创业投资合伙企业（有限合伙）合伙协议》，共同投资名为"扬州君江创业投资合伙企业 （有限合伙）"的私募股权投资基金（以下简称"扬州君江基金"）。根据合伙协议约定，该基金总规模 为人民币 14,520.00万元，公司拟作为有限合伙人（LP）出资人民币 5,350.00 万元，占基金认缴出资总 额的 36.8457%；公司关联方卢凤仙女士拟作为有限合伙人（LP）出资人民币2,600.00 万元，占基金 ...

Core Viewpoint - KKR has announced a new round of investment in Sylvan, a leading global mushroom cultivation and fungal biotechnology company, through its managed dollar and RMB funds, including its first RMB fund [1] Group 1: Company Overview - Sylvan is backed by Jiangsu Yuguan Modern Agricultural Technology Co., Ltd., founded by Huang Jianguang, known as the "Mushroom King" in China [2] - Huang Jianguang started his mushroom business in the 1980s, leading to significant market share in canned mushrooms, with his company producing 68% of the canned mushrooms exported from China to the U.S. [4] - Jiangsu Yuguan was established in 2010 to cultivate high-quality fresh white mushrooms, which account for 40% of the edible mushroom market globally [4] Group 2: Investment Details - KKR's initial investment in Jiangsu Yuguan was approximately 2 billion RMB, which helped the company become the largest single production unit for white mushrooms globally [4] - KKR facilitated the full acquisition of Sylvan and its research laboratories by Jiangsu Yuguan, expanding its global operational footprint [5] - The latest investment aims to support Sylvan's expansion plans, including capacity enhancement, R&D strengthening, and product line diversification in the rapidly industrializing Asian mushroom and bioproducts market [5] Group 3: KKR's Investment Strategy - KKR's assets under management (AUM) reached $723 billion (approximately 5 trillion RMB) as of September 30, 2025, with a diverse portfolio across private equity, private credit, and real estate [7] - KKR has been actively increasing its investments in Chinese assets, including the establishment of its first onshore RMB fund in Shanghai [6][7] - The firm recently completed a $2.5 billion (approximately 17 billion RMB) fundraising for an Asian private credit fund, focusing on high-quality credit assets in the Asia-Pacific region [7][8]

Core Viewpoint - KKR has announced an additional investment in Sylvan, a leading mushroom cultivation and fungal biotechnology company, through its managed USD and RMB funds, marking a continued commitment to support the company's expansion plans [2][7]. Group 1: Company Background - Sylvan is backed by Jiangsu Yuguan Modern Agricultural Technology Co., founded by Huang Jianguang, known as the "Mushroom King" in China [3]. - Huang Jianguang started his mushroom business in the 1980s, leading to his company becoming a major player in the canned mushroom market, with 68% of canned mushrooms exported from China being produced by his enterprise [5]. - In 2010, Jiangsu Yuguan began cultivating high-quality fresh white mushrooms, which account for approximately 40% of the edible mushroom market globally [6]. Group 2: Investment Details - KKR's initial investment in Jiangsu Yuguan was approximately RMB 2 billion in 2018, which helped the company become the largest single production unit for white mushrooms globally, generating revenues of RMB 500 million [6]. - The recent investment round was led by KKR and included participation from several global investors, such as TPG NewQuest, Ping An Capital, and Schroders Capital [6][7]. Group 3: Market and Growth Potential - The new investment will support Sylvan's plans to enhance production capacity, strengthen R&D capabilities, and expand into high-growth product lines, particularly in the rapidly industrializing mushroom and bioproduct markets in Asia [7]. - KKR's assets under management (AUM) reached USD 723 billion (approximately RMB 5 trillion) as of September 30, 2025, indicating its significant presence in private equity and credit markets [9].

Core Viewpoint - Jianghuai Microelectronics has announced a change in control, with its major shareholder, Zibo Xingheng Tusheng, transferring 23.96% of its shares to Shanghai Fuxun Technology for a total price of 1.847 billion yuan, resulting in a profit of approximately 430 million yuan for the seller [1][2][12]. Group 1: Share Transfer Details - Zibo Xingheng Tusheng will transfer 92.38 million shares at a price of 20 yuan per share, totaling 1.847 billion yuan, which is about 7% lower than the closing price before the suspension [4][15]. - After the transfer, the controlling shareholder will change from Zibo Xingheng Tusheng to Shanghai Fuxun Technology, which is a newly established company primarily owned by Shanghai Huayi Holdings Group [5][15]. Group 2: Financial Performance - Jianghuai Microelectronics reported revenues of 939 million yuan, 1.03 billion yuan, and 1.099 billion yuan for the years 2022, 2023, and 2024 respectively, with net profits of 106 million yuan, 105 million yuan, and 98.63 million yuan [16]. - In the first three quarters of 2025, the company achieved a revenue of 910 million yuan, a year-on-year increase of 10.92%, but net profit decreased by 8.66% to 78.78 million yuan [16]. Group 3: Background of Zibo Xingheng Tusheng and Hengsong Capital - Zibo Xingheng Tusheng is backed by Zibo City Asset Operation Group, which holds 99% of its shares, while Hengsong Capital holds 1% and has been involved in previous investments, including a similar transaction with Dongjie Intelligent [8][18]. - Hengsong Capital, founded around 2014, specializes in cross-border and private equity investments, managing over 14 billion yuan in funds and having invested in various sectors including industrial technology and healthcare [3][19].

Group 1: Funding Sources - The funding sources for national-level merger and acquisition (M&A) funds globally fall into three categories: public pensions, sovereign wealth funds, and diversified fundraising [3][8] - Public pensions, according to OECD data, allocated 25.9% of their assets to alternative assets in 2022, with private equity accounting for 55.2% of that, indicating that approximately 7.1% of OECD public pension reserves are directed towards M&A strategies [8] - Sovereign funds, such as Singapore's Government Investment Corporation (GIC), have historically allocated over half of their private equity investments to acquisition strategies, with Middle Eastern sovereign wealth funds playing a dominant role in regional M&A markets [8][9] Group 2: M&A Targets - National-level M&A funds focus on two dimensions: mature assets and strategic sectors [10] - They act as a "relay baton" by not only investing in target companies but also facilitating exits for early shareholders, such as private equity and venture capital funds, thus promoting capital circulation [10] - In strategic sectors, M&A funds aim to protect core assets and enhance supply chain security, as seen in Japan's JIC acquiring semiconductor leader JSR to maintain national technological advantages [11][12] Group 3: Governance and Exit Strategies - Governance structures emphasize professionalism, independence, and sustainability, with a focus on "government guidance and market dominance" to ensure investment decisions remain professional and free from political interference [13] - For example, GIC operates under legal protections that limit government intervention in investment decisions, while Japan's JIC employs a professional management team for its private equity activities [13][14] - Exit mechanisms are designed to ensure liquidity and reinvestment capabilities, with plans for public offerings or sales post-acquisition, as demonstrated by JIC's strategy for JSR [14]

Group 1 - The core viewpoint of the article highlights the successful completion of the fundraising for the Hubei Port and Shipping Development Private Equity Investment Fund, which has raised approximately 2.8 billion yuan after the expansion [2] - The fund is managed by China Merchants ZhiYuan Capital and involves collaboration with Hubei Port Investment Co., Ltd. and Hubei Port Capital Co., Ltd. [2] - The Jianghan District Strategic Emerging Industry Development Guidance Fund has participated in the fundraising, contributing 150 million yuan through Wuhan Sanheng Investment Holding Group [2]